Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 56.7%.

  • Viridian Therapeutics, Inc.\DE's EBIT Margin rose 970130700.0% to 56.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 463.52%, marking a year-over-year increase of 932590000.0%. This contributed to the annual value of 99018.21% for FY2024, which is 179831800.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's EBIT Margin stood at 56.7%, which was up 970130700.0% from 142356.0% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's EBIT Margin's 5-year high stood at 56.7% during Q3 2025, with a 5-year trough of 142356.0% in Q2 2025.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's EBIT Margin had a median value of 71144.44% in 2023 and averaged 57473.73%.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's EBIT Margin tumbled by -707779500bps in 2023 and then soared by 970130700bps in 2025.
  • Viridian Therapeutics, Inc.\DE's EBIT Margin (Quarter) stood at 13589.25% in 2021, then plummeted by -244bps to 46729.52% in 2022, then crashed by -112bps to 99275.0% in 2023, then dropped by -22bps to 121488.89% in 2024, then surged by 100bps to 56.7% in 2025.
  • Its EBIT Margin was 56.7% in Q3 2025, compared to 142356.0% in Q2 2025 and 130369.44% in Q1 2025.